Source: Mark Derewicz, WRAL TECHWIRE, 2/9/21

 An experimental drug created at a subsidiary of Emory University has shown potential to both prevent and treat COVID-19, according to researchers at UNC-Chapel Hill. The drug, known as EIDD-2801, is being developed by Miami-based Ridgeback Biotherapeutics. Ridgeback is partnered with drug giant Merck in the development process. The drug was invented at Drug Innovations at Emory, a not-for-profit biotechnology company wholly owned by Emory University, according to Ridgeback.

For more of this story, click here.